SCLX's Business Model
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Sector & Industry | Healthcare / Drug Manufacturers - General |
| Website | https://www.scilexholding.com |
| CEO (Chief Executive Officer) | Henry H. Ji |
| Number of Employees | |
| IPO date | March 5, 2021 |
SCLX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 960 San Antonio Road |
| City | Palo Alto |
| State | CA |
| Phone | 650-516-4310 |
| Zip Code | 94303 |
| Other Identifiers | |
| CIK | 0001820190 |
| ISIN | US80880W2052 |
| CUSIP | 80880W205 |
| Open | 7.85 |
| Previous Close | 8.01 |
| Volume | 21.7 Thou. |
| Average Volume | 75.51 Thou. |
| Day’s Range | 7.8301 – 8.2 |
| 52 Week Range | 3.6-34.27 |
| MA (50) | 11.7072 |
| MA (200) | 13.5219 |
| Market Cap | 69.36 Mil. |
| Shares Out. | 8.54 Mil. |
| Earnings Date | Mar 12, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
